$36.650
-0.227 (-0.62%)終値時点
OMCL のニュース
OMCL のイベント
Omnicell Reports Q3 Revenue of $308M, Exceeds Expectations
Reports Q3 revenue $308M, consensus $304.48M. "We delivered solid Q3 results and continued to execute against our strategic priorities," said CEO Randall Lipps. "We believe our performance reflects the discipline we have built into the business throughout the year, combined with continued customer interest in solutions that are designed to improve efficiency, safety, and workforce productivity across medication management. At the same time, we continue to see strong momentum with our next-generation platform, backed by a growing pipeline. Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform, intended to improve productivity, efficiency, and workflow reliability. As we see health systems seek greater visibility and connectivity across the medication-use process, we believe Omnicell Titan XT and OmniSphere position us to capitalize on a significant long-term opportunity we see in autonomous medication management."
Sees 206 Revenue at $1.225B-$1.231B, Consensus $1.24B
Sees 206 revenue $1.225B-$1.231B, consensus $1.24B.
Company Sees Q4 Revenue of $295M-$301M
Sees Q4 revenue $295M-$301M, consensus $310.44M.
TraceLink Integrates Drug Supply Chain Compliance Solution with Omnicell
TraceLink announced an integration between its Drug Supply Chain Security Act compliance solution and the pharmacy inventory management systems of Omnicell. This integration is expected to enable hospitals and health systems to manage product verification, traceability, and compliance as part of everyday medication receiving workflows.
Sees 2026 Revenue at $1.23B-$1.25B
Sees 2026 revenue $1.23B-$1.25B, consensus $1.25B.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。